These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 21368164)
1. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164 [TBL] [Abstract][Full Text] [Related]
2. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Garrett JT; Olivares MG; Rinehart C; Granja-Ingram ND; Sánchez V; Chakrabarty A; Dave B; Cook RS; Pao W; McKinely E; Manning HC; Chang J; Arteaga CL Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5021-6. PubMed ID: 21385943 [TBL] [Abstract][Full Text] [Related]
3. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399 [TBL] [Abstract][Full Text] [Related]
4. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Chandarlapaty S; Sawai A; Scaltriti M; Rodrik-Outmezguine V; Grbovic-Huezo O; Serra V; Majumder PK; Baselga J; Rosen N Cancer Cell; 2011 Jan; 19(1):58-71. PubMed ID: 21215704 [TBL] [Abstract][Full Text] [Related]
5. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973 [TBL] [Abstract][Full Text] [Related]
6. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797 [TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832 [TBL] [Abstract][Full Text] [Related]
8. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Serra V; Scaltriti M; Prudkin L; Eichhorn PJ; Ibrahim YH; Chandarlapaty S; Markman B; Rodriguez O; Guzman M; Rodriguez S; Gili M; Russillo M; Parra JL; Singh S; Arribas J; Rosen N; Baselga J Oncogene; 2011 Jun; 30(22):2547-57. PubMed ID: 21278786 [TBL] [Abstract][Full Text] [Related]
9. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167 [TBL] [Abstract][Full Text] [Related]
10. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355 [TBL] [Abstract][Full Text] [Related]
11. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887 [TBL] [Abstract][Full Text] [Related]
13. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. Way TD; Kao MC; Lin JK J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723 [TBL] [Abstract][Full Text] [Related]
14. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376 [TBL] [Abstract][Full Text] [Related]
15. FOXO1A is a target for HER2-overexpressing breast tumors. Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Gayle SS; Arnold SL; O'Regan RM; Nahta R Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997 [TBL] [Abstract][Full Text] [Related]
17. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757 [TBL] [Abstract][Full Text] [Related]
18. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models. Foster P; Yamaguchi K; Hsu PP; Qian F; Du X; Wu J; Won KA; Yu P; Jaeger CT; Zhang W; Marlowe CK; Keast P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Engell K; Bentzien F; Lam ST; Dale S; Yturralde O; Matthews DJ; Lamb P; Laird AD Mol Cancer Ther; 2015 Apr; 14(4):931-40. PubMed ID: 25637314 [TBL] [Abstract][Full Text] [Related]
19. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798 [TBL] [Abstract][Full Text] [Related]
20. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]